Under these conditions, peptide and gemcitabine, as monotherapies, had only a marginal effect on tumor growth, as expected given the low dose of both drugs (equimolar to physiological concentrations of CCN3 for the peptides and suboptimal for gemcitabine) and the late start of peptide treatment (day 11) compared to the earlier treatment of Figure 2. Here, CCN3 is linked to neoplasm.